Category: News

Azenta Life Sciences and Frenova, a division of Fresenius Medical Care and a leader in renal precision medicine, have announced a strategic partnership to advance genomic research in nephrology. The collaboration will support Frenova’s MyReason® genomics research program, which aims to deepen understanding of cardio-kidney-metabolic (CKM) diseases and drive innovation in precision medicine.

The partnership is expected to significantly enhance data generation and genomic sequencing efforts that support research into genetic mechanisms behind kidney disease, helping shape the future of personalized treatment strategies.

MyReason®: A Landmark in CKM Research
Frenova’s MyReason® program is a groundbreaking initiative that already includes over 35,000 participants, with plans to expand to 50,000 over the next two years. Participants provide biospecimens used to study genomic, phenotypic, and clinical data. The data powers the Nephronomics Atlas a key resource supporting genomic exploration of CKM diseases.

The research aims to uncover novel therapeutic targets, disease subtypes, and genetic safety variants using advanced AI and machine learning models trained on this extensive dataset. Frenova and its partner Nephronomics are at the forefront of transforming CKM care through targeted therapeutic discovery.

Azenta’s Role in the Partnership
Azenta will play a vital role by delivering high-quality genomic sequencing via GENEWIZ and managing long-term biospecimen storage through its global biorepository network. With a strong track record in multiomics analysis and sample management, Azenta is positioned to support the complexity and scale of the MyReason® program.

Leadership Perspectives
Ginger Zhou, President of GENEWIZ, commented:

“We are excited to collaborate with Frenova and Nephronomics and support the MyReason research program. This partnership aligns with our mission to empower the scientific community with advanced genomic solutions.”

Jan Walter, President of Frenova, emphasized the significance of the project:

“This broad genome sequencing initiative symbolizes a vital milestone in our journey to form the most reliable genotype-phenotype database for CKM patients. We are excited to partner with Nephronomics to expand the Nephronomics Atlas and unlock insights that could transform patient care.”

Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting

James Sietstra, Founder of Nephronomics, added:

“The expertise in nephrology and Frenova’s MyReason initiative, merged with Azenta’s innovative genomic sequencing and sample management solutions, shows significant cornerstones of the Nephronomics Atlas. This partnership will help us advance scientific understanding and introduce new diagnostics and therapies for CKM conditions.”

Driving Forward Precision Medicine
The collaboration between Azenta, Frenova, and Nephronomics represents a significant leap forward in genomic-driven precision medicine. By integrating powerful genomic tools with clinical insights, the partnership seeks to accelerate discovery and deliver new hope for patients battling CKM diseases worldwide.

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com

Zenara Pharma Private Limited, a leading Biophore company, has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Sertraline Hydrochloride Capsules (150 mg and 200 mg). This marks the first-ever FDA-approved generic equivalent of the reference drug listed by Almatica Pharma, LLC.

The product has also been granted Competitive Generic Therapy (CGT) designation by the FDA. As the first approved applicant through this designation, Zenara has secured 180 days of exclusive marketing rights in the United States, effective from the product’s commercial launch.

Addressing Mental Health with Affordable Solutions

Sertraline Hydrochloride, a selective serotonin reuptake inhibitor (SSRI), is primarily prescribed for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD) in adults and pediatric patients aged six and above. The medication plays a critical role in improving mood, promoting relaxation, and enhancing quality of life especially in today’s fast-paced world where mental well-being is often neglected.

According to IQVIA™ sales data, U.S. sales of the branded reference product reached approximately $35.5 million for the 12-month period ending June 2025, highlighting strong market potential for Zenara’s newly approved generic.

Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting

A Milestone in Innovation and Access

This FDA approval not only reinforces Zenara’s strength in research and development but also represents a significant advancement in providing cost-effective mental health treatments. The company views this milestone as a major step in its mission to deliver safe, high-quality, and affordable pharmaceuticals to global markets.

Leadership Insight

Dr. Srinivas Arutla, CEO of Zenara Pharma, expressed pride in the achievement, stating:

“The first generic approval for sertraline hydrochloride capsules spotlights Zenara’s robust R&D potential and operational excellence. We are committed to our mission of serving patients with high-quality, early, and affordable pharmaceuticals.”

Looking Ahead

Zenara continues to expand its global footprint and aims to play a leading role in advancing healthcare through innovation. The successful approval and market exclusivity of Sertraline Hydrochloride Capsules positions the company as a key player in the treatment of major depressive disorders and supports its ongoing commitment to mental health solutions.

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com

Silexion Therapeutics Corp., a global clinical-stage biotech company specializing in RNA interference (RNAi) therapies, has announced outstanding new preclinical data for its investigational drug, SIL204, designed to target KRAS mutations in various cancers. The data revealed inhibition rates of 97% in pancreatic cancer cells and 90% in colorectal cancer cells, marking a significant step forward in developing therapies for some of the most aggressive forms of cancer.

The results represent the company’s first evidence of safety and efficacy against the KRAS Q61H mutation, a clinically important but previously untested target in human cancer cells. SIL204 continues to demonstrate its promise as a pan-KRAS therapeutic candidate, addressing multiple KRAS mutations across cancer types.

Building on Prior Studies

The new data builds upon earlier studies that tested SIL204’s activity across various cancer models. Using CellTiter-Glo (CTG) analysis, researchers performed a direct comparison of SIL204’s effectiveness against multiple KRAS mutations. The study also showed dose-dependent inhibition of up to 94% in pancreatic cells with KRAS G12D mutations, and notably, 87% inhibition in cells with the KRAS Q61H mutation, a mutation previously unexplored by Silexion.

These results follow earlier findings that demonstrated SIL204’s effectiveness in lung cancer cell lines, providing further validation of Silexion’s lipid-conjugated delivery platform for RNAi-based cancer therapeutics.

Executive Insight

Silexion Chairman and CEO Ilan Hadar commented on the development:

“These findings have provided engaging evidence of SIL204’s potential activity against various KRAS mutations across multiple cancer types. The capability to achieve such a level of inhibition in colorectal and pancreatic cancer models with multiple KRAS mutations exponentially strengthens SIL204’s ability as a pan-KRAS therapeutic candidate.”

Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting

He added:

“With these positive results in all three crucial KRAS-targeted cancer types lung, pancreatic, and colorectal—we are elevating our confidence in SIL204’s potency to address major unmet needs for severe cancer patients.”

Path Forward

Silexion is now preparing to advance SIL204 into Phase 2/3 clinical trials in Q2 2026, focusing on KRAS-driven solid tumors. The trials will incorporate both systemic and intratumoral delivery approaches, part of the company’s dual-path administration strategy aimed at maximizing therapeutic impact.

The strong preclinical evidence across multiple KRAS mutations positions SIL204 as a potentially transformative treatment option in the oncology space, particularly for patients battling treatment-resistant forms of cancer.

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com

Canada and the UK have joined forces in a groundbreaking project aimed at developing next-generation immunotherapies for malignant melanoma, a life-threatening form of skin cancer. The initiative, led by Canadian biotech firm Genvira Biosciences Inc., UK-based LabSkin Limited, and the National Research Council of Canada (NRC), has received a major funding boost of approximately €1.2 million ($2.0 million CAD) under the Canada-UK Biomanufacturing of Biologics and Advanced Therapies Program.

The funding comes from both Innovate UK, part of UK Research and Innovation (UKRI), and Canadian government programs, including the NRC’s Collaborative Science and Technology Innovation Program (CSTIP) and the NRC Industrial Research Assistance Program (IRAP).

Addressing a Global Health Challenge

Malignant melanoma continues to pose a serious public health challenge globally, with an estimated 330,000 new cases and 60,000 deaths annually. The joint project aims to accelerate the development of innovative cancer vaccines and antigen delivery systems by combining each partner’s core strengths in biotechnology.

Cutting-Edge Collaboration

As part of the initiative:

LabSkin Limited will leverage its expertise in disease modeling to develop a sophisticated 3D human skin model of melanoma for in vitro testing of vaccine candidates.

Genvira Biosciences will contribute its proprietary viral vector and gene delivery platforms.

The NRC will integrate its mRNA technology capabilities to engineer targeted immunotherapies.

This consortium brings together advanced know-how in viral vectors, mRNA technologies, 3D tissue engineering, and scalable biomanufacturing. The project will also emphasize rapid, quality-controlled production processes essential for future healthcare readiness.

Leadership Comments

Dr. Nicola Kingswell, Scientific Director at LabSkin Limited, expressed gratitude for the funding support, stating,

“We’re thankful to Innovate UK for contributing to the project. It symbolizes a positive change in the treatment of malignant melanoma, which will benefit many patients globally. This collaboration will produce and validate new immunotherapies. It has also established an excellent framework for developing next-generation cancer therapeutics.”

Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting

Dr. Jiahu Wang, President of Genvira Biosciences, added,

“Firstly, huge thanks to NRC IRAP for their support and the NRC for their effective partnership role. This collaboration helps us to continuously translate our viral vector technologies into clinical applications for melanoma. It helps us to broaden advancement in cancer immunotherapy.”

Strengthening International Innovation

This cross-border initiative underscores the value of international collaboration in tackling pressing global health challenges. By pooling expertise, infrastructure, and funding, the project aims to deliver faster, more effective solutions for cancer treatment and potentially set a new benchmark for immunotherapy innovation.

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com

W Health Ventures has unveiled its second fund worth $70 million to support the development of healthcare startups in India, signaling a strong commitment to advancing the country’s next-generation medical infrastructure. This initiative aims to empower early-stage companies from the ground up and foster innovation in AI-driven healthcare solutions and single-specialty care models tailored for the Indian market.

The fund’s rollout comes amid cautious optimism in the private equity space, with other firms like Fireside Ventures and Nexus Venture Partners also preparing new rounds. W Health’s strategic focus mirrors the shifting venture capital landscape, which now leans toward deep research, focused theses, and sustainable investment models.

Focus Areas: AI and Single-Specialty Healthcare
The fund centers on two core themes:

• AI-powered B2B healthcare services
• Single-specialty care delivery models

These themes are backed by in-depth research, including interviews with patients and healthcare professionals, to identify pain points and opportunities for scalable, tech-enabled solutions.

The ‘Company Creation’ Approach
W Health Ventures will support 8 10 startups over the next four years using its unique “company creation” model. Unlike traditional VCs that back externally formed companies, W Health incubates ideas internally, validates them, and then pairs them with external founders to scale.

The firm plans to invest $3–$5 million in early-stage rounds, with follow-on investments of similar size. The fund size could potentially grow to $100 million by final close, underscoring investor confidence in India’s growing healthtech ecosystem.

Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting

Leadership Insights
Dr. Pankaj Jethwani, Managing Partner at W Health Ventures, shared with Moneycontrol:

“This second fund strengthens our company creation model, which we’ve developed through years of trial and refinement. We’re committed to building impactful startups that solve real-world healthcare challenges.”

Speaking on the transformative role of technology in patient care, he added:

“Cancer patients, for instance, often struggle due to limited access. AI has the potential to bridge that gap. India is already the world’s pharmacy and AI-powered healthcare will be our next great contribution to the world.”

With this fund, W Health Ventures is not just investing in startups it is investing in the future of global healthcare, starting with India’s rapidly evolving medtech landscape.

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com

In a significant step toward bolstering public health preparedness, Moderna Inc. has received commercial authorization from the European Commission (EC) for its updated COVID-19 vaccine, Spikevax, targeting the SARS-CoV-2 variant LP.8.1. The vaccine is approved for active immunization in individuals aged six months and older.

This authorization follows a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The vaccine update aims to provide enhanced protection against evolving strains of the virus and is expected to be available across all 27 EU member states, including Norway, Iceland, and Liechtenstein, during the 2025–2026 vaccination cycle.

Moderna, a leader in mRNA technology, continues to innovate in the fight against infectious diseases. With this latest approval, the company strengthens its global strategy to address current and future public health threats.

A Step Toward Future Readiness
The updated Spikevax vaccine underwent rigorous clinical evaluations before approval. Moderna aims to improve upon previous formulations that had mixed public reception due to concerns over side effects. The new version is designed to boost immunity more effectively, preparing populations for potential future outbreaks and offering stronger, more targeted protection.

Ongoing Global Review and Rollout Plans
Moderna’s updated vaccine formulation is also under regulatory review in other countries. The company is aligning with global health authority guidelines as it continues to expand access to mRNA-based vaccines. Common side effects such as fatigue, chills, headache, and muscle pain remain expected post-injection, as with previous COVID-19 vaccine versions.

Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting

Leadership Comments
Stéphane Bancel, Chief Executive Officer of Moderna, expressed appreciation for the European Commission’s swift action:

“We are grateful for the EC’s timely review and are proud to offer our updated COVID-19 vaccine to help protect people across Europe. COVID-19 continues to challenge global health systems, and this approval reinforces our commitment to public health. We encourage individuals to speak with their healthcare providers about receiving the updated vaccine.”

With this approval, Moderna reinforces its position as a global pioneer in vaccine development, committed to protecting communities through science-driven, next-generation medical solutions.

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com

Alafair Biosciences, a leading innovator in medical device solutions for soft-tissue protection in orthopedic surgery, has received FDA 510(k) clearance for its Versacoat™ nerve protector and tendon protector, launched as a single product: Versacoat™ flowable hydrogel.

Designed to reduce post-operative tethering in procedures involving skeletal muscle, peripheral nerves, ligaments, and tendons, Versacoat provides a safe, gliding surface that enhances healing across a broad range of age groups and surgical specialties.

The hydrogel utilizes Alafair’s proprietary alginate-based, collagen-free formulation—the same technology behind the company’s successful Versawrap™ hydrogel sheet. The product delivers hyaluronic acid, known to aid early soft tissue recovery by reducing inflammation and promoting hydration, while the alginate bioresorbs, ensuring natural tissue recovery without residual material.

This latest clearance strengthens Alafair’s position in the expanding surgical biomaterials market. Versawrap™, with over 30,000 successful implants, has already gained widespread recognition among surgeons and healthcare organizations, setting the stage for Versacoat’s adoption.

Dr. Samuel B. Adams Jr., M.D., FAAOS, FAOA, Associate Professor of Orthopedic Surgery at Duke University Medical Center, praised the new development:

“Post-operative complications like pain and limited mobility can be significant. Versawrap has consistently helped my patients recover more quickly, and I see great promise in Versacoat’s ability to treat complex injuries with its syringe-deliverable format.”

Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting

John Joyoprayitno, President and CEO of Alafair Biosciences, added:

“Versawrap’s success has been a testament to our technology’s effectiveness. With Versacoat flowable hydrogel, we’re addressing surgeon feedback for a more versatile and high-volume format, making it suitable for minimally invasive procedures and hard-to-reach tissues across multiple specialties like sports medicine, trauma, and extremities.”

This milestone marks a significant advancement in post-surgical soft tissue care, with Versacoat poised to make a meaningful impact on patient outcomes and recovery efficiency.

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com

Kedrion Biopharma has announced that its human coagulation factor X concentrate, COAGADEX®, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of acquired factor X deficiency (AFXD), a rare hematologic disorder affecting fewer than one in a million individuals globally.

The FDA has also issued a “study may proceed” letter, clearing the way for a clinical trial to evaluate the safety and efficacy of COAGADEX in managing peri-operative bleeding and treating active bleeding episodes in patients with AL amyloidosis a key cause of AFXD. The trial aims to assess COAGADEX’s potential in restoring hemostasis in vulnerable patient populations.

COAGADEX is a plasma-derived human coagulation factor concentrate that has already received approval in approximately 38 countries for the treatment of hereditary factor X deficiency (HFXD) in both adults and children. It is used for routine prophylaxis, on-demand bleeding treatment, and perioperative bleeding management in mild to severe cases. While COAGADEX is manufactured by Bio Products Laboratory Limited, its distribution in the United States is handled by Kedrion Biopharma Inc.

Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting

Commenting on the FDA designation, Bob Rossilli, Chief Commercial Officer and U.S. General Manager at Kedrion Biopharma, stated, “The orphan drug designation for COAGADEX in AFXD is a significant milestone. It highlights the urgent need for new therapies in this underserved area and underscores our commitment to advancing care for patients with rare diseases. We now look forward to the results of the clinical trial.”

Dr. Nisha Jain, VP of Global Clinical Development and Strategy at Kedrion, added, “This study marks a critical step in exploring COAGADEX’s broader therapeutic potential. By focusing on AFXD linked to amyloidosis, we are reinforcing our dedication to precision medicine in rare bleeding disorders. The FDA’s support validates the importance of our mission.”

The new designation represents a key advancement in global rare disease treatment efforts and expands the potential reach of COAGADEX in the management of bleeding disorders beyond hereditary indications.

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com

enecard PBF, a pioneer in pharmacy benefit facilitation, has announced a strategic partnership with DecisionRX, Inc., a leader in medication therapy optimization (MTO), to deliver personalized, data-driven medication guidance for clients and members worldwide.

The collaboration combines DecisionRX’s advanced pharmacogenomics platform and analytics with Benecard PBF’s outcome-based, transparent benefit model, aiming to improve health outcomes, minimize medication failures, and generate cost savings for health plans and employers.

A New Standard in Pharmacy Benefit Management
As part of the partnership, both organizations will share equal responsibility and commitment. DecisionRX brings its MTO solution to the table leveraging clinical pharmacists, prescription intelligence, and genomic data to assess the effectiveness, safety, and personalization of treatments. Meanwhile, Benecard PBF continues to elevate its pharmacy benefits offering through its member-first approach and auditable, transparent pricing model.

Together, they will offer value-based, risk-sharing options for plan sponsors, aligning financial incentives with measurable health improvements and cost efficiencies.

One of the key benefits of the partnership is the ability to reduce trial-and-error prescribing. Patients and providers will receive medication guidance based on genomic and claims data, helping to enhance therapeutic precision and reduce unnecessary healthcare spending.

Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting

DecisionRX’s MTO platform has shown potential to reduce the annual cost of care by $1,200 for individuals under 65 and by $3,600 per Medicare patient, according to internal estimates.

Leadership Perspectives
Jeff Shea, President of Benecard PBF, emphasized the transformative nature of the alliance:

“At Benecard PBF, we’ve always believed in the power of pharmacogenomics. This partnership is more than just innovation it’s about turning insights into real-time, evidence-based care. Our role goes beyond managing benefits we’re here to facilitate better health outcomes.”

Travis Morgan, Co-founder and President of DecisionRX, expressed optimism about the collaboration:

“We’re thrilled to work with Benecard PBF to bring our MTO platform to a broader population. Benecard truly understands that medication therapy optimization is not just about cutting costs it’s about maximizing impact on patient lives.”

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com